Is compounded tirzepatide still legal to buy online in 2026? FDA’s dated statements
Is compounded tirzepatide still legal to buy online in 2026?
FDA has not published a single yes or no; its dated records say the tirzepatide injection shortage was resolved on December 19, 2024 (after an October 2, 2024 decision was sent back for reevaluation), and the grace periods FDA announced for compounders ended on March 5, 2025 for state-licensed pharmacies (503A) and March 19, 2025 for outsourcing facilities (503B). On April 1, 2026 FDA stated that tirzepatide is on neither the 503B bulks list nor its drug shortage list, and on April 30, 2026 it proposed not adding it to the 503B bulks list.
This page lists what FDA has published, with dates. It is not legal advice and does not say whether any company’s product is lawful.
FDA’s statements describe conditions under which compounding can qualify for exemptions in sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. For how the two kinds of compounder differ, see 503A pharmacies and 503B outsourcing facilities.
FDA’s statements, by date
- Oct 2, 2024: FDA announced it had determined that the shortage of tirzepatide injection was resolved. In October 2024 that decision was remanded to FDA for reevaluation as part of litigation. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Dec 19, 2024: After reevaluating, FDA issued a new decision that the tirzepatide injection shortage is resolved. FDA said it did not intend to take action, for violations that depend on tirzepatide being on the shortage list, against state-licensed pharmacies (section 503A) until February 18, 2025, or outsourcing facilities (section 503B) until March 19, 2025. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Mar 5, 2025: A federal district court denied the preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:24-cv-00953 (N.D. Tex.). FDA stated (update dated March 10, 2025) that the enforcement discretion period for 503A tirzepatide compounding had ended, and that for 503B outsourcing facilities it ran until March 19, 2025. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Sep 5, 2025: FDA established a “green list” import alert (Import Alert 66-80) for GLP-1 active pharmaceutical ingredients. APIs from facilities on the list may enter; APIs from other sources are subject to detention without physical examination. Source: FDA news release: FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
- Apr 1, 2026: FDA stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list. FDA explained that outsourcing facilities may compound from bulk drug substances only if the substance is on the 503B bulks list or the drug is on the shortage list at the time of compounding, distribution and dispensing. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 1, 2026: FDA restated the section 503A conditions: compounding for an individual patient on a prescription, and not compounding regularly or in inordinate amounts drugs that are essentially copies of a commercially available drug. FDA gave semaglutide combined with vitamin B12 (cyanocobalamin) as an example that may be considered essentially a copy, and said that at this time it does not intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 30, 2026: FDA announced a proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound them from bulk drug substances. FDA said it would consider public comments before a final determination. Source: FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- May 1, 2026: The proposal was published in the Federal Register (Docket No. FDA-2018-N-3240, 91 FR 23431) with comments due June 30, 2026. Source: Federal Register, May 1, 2026: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
- Jun 26, 2026: FDA extended to July 30, 2026 the comment period on its proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list. Source: Federal Register, June 26, 2026: Extension of Comment Period
- Oct 1, 2026: FDA states it has warned companies that sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption,” sold directly to consumers with dosing instructions. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date. Each statement was re-checked against its source page on Nov 15, 2026.
Current status in FDA data (Nov 15, 2026)
- FDA drug shortage list
- No tirzepatide injection listed as a current shortage
- 503B bulks list proposal
- No final determination published in the Federal Register docket FDA-2018-N-3240 as of this date
- FDA warning letters naming compounded tirzepatide
- 95
- Telehealth letters naming tirzepatide issued after the 503B grace period ended
- 87
- Recall reports naming tirzepatide
- 28
Telehealth letters naming tirzepatide since Mar 19, 2025
| False or misleading claims / misbranded | 51 |
| Unapproved or misbranded drugs sold online | 36 |
Common questions
Can telehealth companies still sell compounded tirzepatide after the shortage ended?
FDA’s records set conditions rather than a yes or no: compounding under section 503A needs an individual prescription and may not regularly copy an approved drug, and outsourcing facilities may compound from bulk tirzepatide only if it is on the 503B bulks list or the shortage list, which FDA said on April 1, 2026 it is not. Since Mar 19, 2025, FDA has issued 87 warning letters to telehealth companies naming tirzepatide, most in the group “False or misleading claims / misbranded” (51).
Is tirzepatide on FDA’s drug shortage list?
No tirzepatide injection is listed as a current shortage in FDA’s data as of Nov 15, 2026.
What is the 503B bulks list?
It is FDA’s list of bulk drug substances outsourcing facilities may use in compounding because FDA found a clinical need. On April 30, 2026 FDA proposed not to include semaglutide, tirzepatide and liraglutide; the comment period was extended to July 30, 2026.
Sources
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA news release: FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
- FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- Federal Register, May 1, 2026: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
- Federal Register, June 26, 2026: Extension of Comment Period
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA Drug Shortages (via openFDA drug shortages endpoint)
- FDA warning letters (fda.gov full-text search)
Records last pulled Nov 15, 2026. Every entry links to the original public record.